Display Settings:

Format

Send to:

Choose Destination
    Bull World Health Organ. 2011 Nov 1;89(11):838-45. Epub 2011 Sep 1.

    Can pharmacogenomics improve malaria drug policy?

    Source

    Institute of Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, 120 Mason Farm Road, Chapel Hill, NC 27599-7361, United States of America. mroederer@unc.edu

    Abstract

    Coordinated global efforts to prevent and control malaria have been a tour-de-force for public health, but success appears to have reached a plateau in many parts of the world. While this is a multifaceted problem, policy strategies have largely ignored genetic variations in humans as a factor that influences both selection and dosing of antimalarial drugs. This includes attempts to decrease toxicity, increase effectiveness and reduce the development of drug resistance, thereby lowering health care costs. We review the potential hurdles to developing and implementing pharmacogenetic-guided policies at a national or regional scale for the treatment of uncomplicated falciparum malaria. We also consider current knowledge on some component drugs of artemisinin combination therapies and ways to increase our understanding of host genetics, with the goal of guiding policy decisions for drug selection.

    PMID:
    22084530
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3209725
    Free PMC Article

    Images from this publication.See all images (2) Free text

    Fig. 2
    Fig. 1

      Supplemental Content

      Icon for Scientific Electronic Library Online Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk